Newswise — The U.S. Food and Drug Administration has awarded orphan drug status to a promising immunotherapy …
An immunotherapy developed at Roswell Park Cancer Institute has been granted orphan drug status by the US Food and Drug Administration (FDA). FDA awards orphan drug status to brain cancer vaccine FDA awards orphan status to …
Thinly traded micro cap VBI Vaccines (NASDAQ:VBIV) is up 8% premarket on light ... of Glioblastoma Multiforme (GBM), a common and aggressive type of malignant brain tumor. The company plans to launch a Phase 1/2a clinical trial later …
The US Food and Drug Administration has awarded orphan drug status to a promising immunotherapy vaccine developed at Roswell Park Cancer Institute. The FDA notified MimiVax LLC, a Roswell Park spinoff company, on August 3 that …
the same vaccine you get when you end up in the ER after stepping on a rusty nail – to “prime” the immune systems of patients with brain tumors. Then they administered immunotherapy using a new kind of cellular cancer vaccine that …
Glioblastoma is the most common aggressive primary brain tumor, and despite advances in standard treatment, the median survival is about 15 months (compared to 4 months without treatment). Researchers at Thomas Jefferson …
OKLAHOMA CITY - Doctors at Stephenson Cancer Center are excited about a new development in the fight against brain cancer. Terminal brain tumors are the most deadly form of cancer and one of the most underfunded diseases. Often, …
Oct. 4, 2010 -- A new vaccine for a deadly brain cancer known as glioblastoma doubled the survival time of patients, researchers from Duke University report. The new vaccine, he says, "seems to be twice as good as the standard …
For patients with low-grade gliomas, or slow growing brain tumors, a shot in the arm might soon lead to a new treatment therapy. A groundbreaking, first in humans vaccine will be tested in an early phase clinical trial that will soon begin at …
The U.S. FDA has awarded orphan drug status to SurVaxM, a promising immunotherapy vaccine developed at Roswell …